Hsu Hui-Ping, Yang Ta-Ming, Hsieh Yu-Hsiang, Shan Yan-Shen, Lin Pin-Wen
Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138, Sheng-Li Road, Tainan, 70428, Taiwan, ROC.
Ann Surg Oncol. 2007 Jan;14(1):50-60. doi: 10.1245/s10434-006-9136-3. Epub 2006 Oct 20.
Ampullary cancer has the best prognosis in periampullary malignancy but unpredicted early recurrence after resection is frequent. The current study tried to find the predictors for recurrence to be used as determinative for postoperative adjuvant therapy.
Information was collected from patients who underwent pancreaticoduodenectomy with regional lymphadenectomy for ampullary cancer in high-volume hospitals between January 1989 and April 2005. Recurrence patterns and survival rates were calculated and predictors were identified.
A total of 135 eligible patients were included. The 30-day operative mortality was 3%. Median followup for relapse-free patients was 52 months. Disease recurred in 57 (42%) patients, including 31 liver metastases, 26 locoregional recurrences, 9 peritoneal carcinomatoses, 7 bone metastases, and 6 other sites. Pancreatic invasion (P = 0.04) and tumor size (P = 0.05) were the predictors for locoregional recurrence, while lymph node metastasis was the sole predictor for liver metastasis (P = 0.01). The 5-year disease-specific survival rate was 45.7%; 77.7% for stage I, 28.5% for stage II, and 16.5% for stage III; and 63.7% for node-negative versus 19.1% for node-positive patients. Pancreatic invasion and lymph node involvement were both predictors for survival of patients with ampullary cancer.
Pancreaticoduodenectomy with regional lymphadenectomy is adequate for early-stage ampullary cancer but a dismal outcome can be predicted in patients with lymph node metastasis and pancreatic invasion. Lymph node metastasis and pancreatic invasion can be used to guide individualized, risk-oriented adjuvant therapy.
壶腹癌在壶腹周围恶性肿瘤中预后最佳,但切除术后早期复发常见且难以预测。本研究试图寻找复发的预测因素,以用于确定术后辅助治疗。
收集1989年1月至2005年4月期间在大型医院接受胰十二指肠切除术及区域淋巴结清扫术治疗壶腹癌患者的信息。计算复发模式和生存率,并确定预测因素。
共纳入135例符合条件的患者。30天手术死亡率为3%。无复发患者的中位随访时间为52个月。57例(42%)患者出现疾病复发,包括31例肝转移、26例局部区域复发、9例腹膜种植转移、7例骨转移和6例其他部位转移。胰腺侵犯(P = 0.04)和肿瘤大小(P = 0.05)是局部区域复发的预测因素,而淋巴结转移是肝转移的唯一预测因素(P = 0.01)。5年疾病特异性生存率为45.7%;I期为77.7%,II期为28.5%,III期为16.5%;淋巴结阴性患者为63.7%,淋巴结阳性患者为19.1%。胰腺侵犯和淋巴结受累均为壶腹癌患者生存的预测因素。
胰十二指肠切除术及区域淋巴结清扫术适用于早期壶腹癌,但淋巴结转移和胰腺侵犯的患者预后较差。淋巴结转移和胰腺侵犯可用于指导个体化、基于风险的辅助治疗。